ChemGenex Pharmaceuticals has announced that it has filed for patent protection for a further five novel depression-associated gene targets discovered by its depression and anxiety research group. The discovery follows the recent signing of a major partnership with the leading UK biopharmaceutical company Vernalis plc, a deal worth A$2 million in the first year pending milestones.ChemGenex Pharmaceuticals researchers based at Deakin University in Geelong have identified five genes that are differentially expressed over a period of 8 days as the company’s unique animal model undergoes behavioural changes after separation from littermates. The discoveries take to ten the number of genes that ChemGenex Pharmaceuticals has protected in the field of CNS diseases.
